<DOC>
	<DOCNO>NCT02432547</DOCNO>
	<brief_summary>This 24 month phase IV , randomise , prospective , multicentre , clinical trial laser therapy area peripheral retinal ischaemia combine intravitreal aflibercept versus intravitreal aflibercept monotherapy . Both arm 2mg intravitreal aflibercept accord treat extend protocol . The specific aim study test whether laser therapy peripheral retinal ischaemia reduces overall number intravitreal aflibercept injection require control DMO 24 month period .</brief_summary>
	<brief_title>Laser Therapy Combined With Intravitreal Aflibercept v Intravitreal Aflibercept Monotherapy ( LADAMO )</brief_title>
	<detailed_description>Diabetic retinopathy common cause blindness individual age 20 65 year developed country . Swelling central retina , `` macular oedema '' , common cause visual loss diabetic retinopathy . Recent study suggest peripheral retinal ischaemia contributes macula oedema diabetes retinal vein occlusion . Intravitreal anti-Vascular Endothelial Growth Factor ( VEGF ) therapy , Aflibercept ( Eylea ) show encouraging result manage Diabetic Macular Oedema ( DMO ) . There evidence regular treatment anti-VEGF drug reduces DMO improve vision average . Previous research institution show average 7 11 injection require first year stabilise disease . However , significant burden patient term frequent visit eye specialist , time work repeat injection eye . The purpose study see whether targeted peripheral retinal laser therapy area retina impaired blood supply reduce number intravitreal aflibercept injection require 2 year stabilise DMO .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>At screening , study eye must DMO retinal thickness &gt; 300 micron central 1mm subfield Spectral domain OCT Age &gt; = 18 year Diagnosis diabetes mellitus Best correct visual acuity 3579 LogMAR letter 4 meter ( approximately 6/7.56/60 ) study eye Women childbearing potential must negative urine pregnancy test screen visit prior treatment . A woman consider childbearing potential unless postmenopausal without menses 12 month surgically sterilise Peripheral retinal ischaemia affect area great 10 disc diameter widefield fundus fluorescein angiogram ( per Central Vein Occlusion Study ) Centre involve DMO , opinion investigator , would benefit focal macular laser treatment ( e.g . diffuse leak capillary bed , disruption foveal avascular zone perifoveal capillary dropout , complete macular grid laser ) . Written inform consent obtain Known allergy aflibercept agent use study Women pregnant , nursing , plan pregnancy , childbearing potential use reliable mean contraception Loss vision due cause ( e.g . age related macular degeneration , myopic macular degeneration , retinal vein occlusion ) study eye . Macular oedema due cause study eye . Macula hole , vitreomacular traction significant epiretinal membrane study eye . An ocular condition would prevent visual acuity improvement despite resolution oedema ( foveal atrophy substantial premacular fibrosis ) Treatment intravitreal triamcinolone acetonide ( IVTA ) within last 6 month peribulbar triamcinolone within last 3 month , antiVEGF drug ( bevacizumab , ranibizumab aflibercept ) within last 2 month study eye . Cataract surgery within last 3 month study eye Previous PRP laser treatment study eye Previous vitrectomy study eye Media opacity include cataract already preclude adequate macular photography cataract likely require surgery within 12 month Intercurrent severe disease septicaemia , condition would affect followup photographic documentation ( e.g . geographical , psychosocial ) History chronic renal failure require dialysis renal transplant Blood pressure &gt; 180/110 Patient condition situation investigator 's opinion may put patient significant risk , may confound study result , may interfere significantly patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Diabetic</keyword>
	<keyword>Macular Oedema</keyword>
	<keyword>Retinopathy</keyword>
</DOC>